Elekta Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Elekta Bundle
What is included in the product
Detailed Word Document
Elekta's BCG Matrix assesses product units in Stars, Cash Cows, Question Marks, and Dogs, optimizing investment strategies.
Customizable Excel Spreadsheet
Printable summary optimized for A4 and mobile PDFs, ensuring clear communication of business unit strategies.
Preview = Final Product
Elekta BCG Matrix
The Elekta BCG Matrix preview mirrors the final product you'll get. It's the complete, ready-to-use document designed for easy analysis and presentation, immediately available upon purchase.
BCG Matrix Template
Actionable Strategy Starts Here
Elekta’s BCG Matrix reveals a snapshot of its product portfolio. Stars represent promising areas, while Cash Cows fuel growth. Question Marks need strategic focus; Dogs require careful consideration. This preview is just a starting point. Get the full BCG Matrix report for in-depth analysis and strategic recommendations to guide your investment decisions.
Stars
Elekta Unity MR-Linac
Elekta Unity, a star in Elekta's portfolio, is the first high-field MR-Linac. This innovation merges MRI with radiation therapy, enabling real-time adaptive treatments. In 2024, its revenue contribution is crucial, boosting Elekta's market presence. The technology's precision attracts significant investment, fueling growth.
Elekta Evo
Elekta Evo, launched in 2024, is a "Star" in Elekta's BCG Matrix. This AI-powered system offers workflow automation. It provides online and offline adaptive radiotherapy. Customer feedback in Q3 2024/25 was very positive. Its market share is expected to increase by 15% in 2025.
Elekta ONE
Elekta ONE, a star in Elekta's portfolio, is a recent oncology software innovation. It enhances user experience while maintaining treatment quality, integrating with Elekta Evo. In 2024, Elekta's software revenue increased, reflecting ONE's growing impact. Recognized as 'Best in KLAS,' Elekta ONE offers a comprehensive application suite.
Versa HD
Elekta's Versa HD linear accelerator is positioned as a Star in the BCG Matrix, indicating high market growth and a strong market share. This platform is favored for its high-dose-rate beam delivery and advanced treatment capabilities, crucial for modern radiotherapy. It excels in treating various cancers, including brain metastases, showcasing its versatility. In 2024, Elekta's oncology solutions, including Versa HD, contributed significantly to its revenue.
- Versa HD is a key product for Elekta's oncology segment.
- Offers advanced treatment modalities and motion management.
- Brain metastases solutions are a key feature.
- Elekta's oncology solutions drive revenue growth.
Elekta Esprit
Elekta Esprit, the newest Leksell Gamma Knife, is a Star in Elekta's BCG matrix, indicating high market share and growth potential. It received FDA clearance in October 2022, marking a significant advancement in radiosurgery. This platform offers faster treatment planning and improved accuracy. Elekta's neuroscience solutions, including Esprit, are expected to contribute significantly to the company's revenue in 2024.
- FDA clearance in October 2022.
- Focus on brain disorder treatments.
- Expectation of revenue increase in 2024.
Elekta's Stellar Products: Revenue Drivers Unveiled
Elekta's "Stars" represent high-growth, high-share products driving revenue. Elekta Unity and Evo, launched in 2024, are key innovations. Versa HD and Esprit continue to strengthen Elekta's market position.
| Product | Description | 2024 Revenue Contribution (Est.) |
|---|---|---|
| Elekta Unity | MR-Linac for adaptive treatments | Significant, driving market presence |
| Elekta Evo | AI-powered workflow automation | Expected 15% market share increase in 2025 |
| Elekta ONE | Oncology software suite | Increased software revenue in 2024 |
| Versa HD | Linear accelerator, advanced treatments | Key revenue contributor in 2024 |
| Elekta Esprit | Leksell Gamma Knife | Expected revenue increase in 2024 |
Cash Cows
Linear Accelerators (Linacs)
Elekta's linear accelerators (linacs) are a key component of its "Cash Cows" in the BCG Matrix. Elekta has a substantial installed base of over 7,300 linacs worldwide. The global radiation therapy market, fueled by tech advancements, is projected to grow, thus ensuring stable revenue. Elekta's linacs, like Versa HD, are major revenue contributors.
MOSAIQ Oncology Information System
Elekta's MOSAIQ is a key oncology information system, managing patient data and treatment workflows. It supports various cancer treatments, including radiation therapy. A significant deal in Mexico highlights its market presence. MOSAIQ integrates with the Monaco treatment planning system, enhancing its functionality.
Brachytherapy Applicators and Afterloaders
Brachytherapy applicators and afterloaders are key in HDR procedures, enhancing precision. This segment was the highest revenue-generating in the global breast cancer brachytherapy market in 2024. The market's expansion reflects the need for accurate radiation delivery. Sales in 2024 reached $2.3 billion, showing strong demand.
Elekta Care Services
Elekta Care Services, a significant cash cow for Elekta, focuses on customer satisfaction through services, learning, and community support. These services include Elekta Care Support, Elekta Care 360, Elekta Care Learning, and Elekta Care Community, all designed to boost system uptime and performance. Although specific 2024 revenue figures are not yet available, service revenue typically contributes substantially to Elekta's overall income. In 2023, Elekta's service revenue was a significant portion of total revenue.
- Elekta Care contributes to customer retention.
- Services include Support, 360, Learning, and Community.
- These services aim to increase system uptime and performance.
- Service revenue is a key part of Elekta's income.
Treatment Planning Systems (e.g., Monaco)
Elekta's Monaco treatment planning systems are crucial for radiation therapy, generating steady revenue. These systems are integrated into major agreements and are consistently updated with new features. The acquisition of Philips' Pinnacle TPS patent portfolio strengthens Elekta's market standing. This segment provides a reliable income source, essential for consistent performance. In 2024, this area saw a 5% revenue increase.
- Steady Revenue: Treatment planning systems provide a stable income.
- Continuous Updates: New features keep the systems competitive.
- Strategic Acquisition: Philips' patent portfolio boosts Elekta.
- Financial Performance: This segment grew by 5% in 2024.
Stable Revenue Streams: The Company's Key Offerings
Elekta's "Cash Cows" provide stable revenue through established products and services. These include linacs with over 7,300 installations, and MOSAIQ, crucial for managing patient data. Brachytherapy and Care Services also drive revenue, with services showing strong contributions.
| Product/Service | Description | 2024 Revenue (Estimate) |
|---|---|---|
| Linacs | Radiation therapy machines | Significant, based on installed base |
| MOSAIQ | Oncology information system | Steady, with market presence |
| Brachytherapy | Precision radiation delivery | $2.3 billion market in 2024 |
| Elekta Care Services | Customer support and services | Substantial, service revenue |
Dogs
Legacy Brachytherapy Products
Elekta's legacy brachytherapy products, facing competition, might be "dogs." Although the brachytherapy market is projected to hit USD 1.88 billion by 2035, older tech could lose share. Newer methods often offer advantages. Competitors' advancements further challenge these older offerings.
Products with Declining Market Share
Dogs are products in low-growth markets with low market share. Elekta's U.S. and China net sales were hit by lower volumes in 2024. Minimizing these products is crucial. For example, in Q1 2024, Elekta reported a decline in order intake. Products in this category are struggling.
Outdated Software Versions
Outdated software, not part of Elekta ONE, fits the "dog" category. These older versions may lack competitiveness compared to newer, integrated solutions. Maintaining software relevance requires regular updates and integration. In 2024, approximately 15% of Elekta's revenue came from older, non-integrated systems, signaling a need for strategic upgrades.
Products Facing Intense Competition
Elekta's products, especially those competing with the likes of Varian and Siemens Healthineers, could be classified as "dogs" if they struggle to maintain market share. Healthineers represents a significant competitive threat, and Elekta's performance hinges on Unity's continued adoption and its ability to fend off rivals. The company's financial results reflect this dynamic. For example, in fiscal year 2023/2024, Elekta's order intake decreased by 1% at constant exchange rates, which shows the pressure.
- Order intake decreased by 1% at constant exchange rates in fiscal year 2023/2024.
- Healthineers poses a formidable competitive challenge.
- Unity's adoption is crucial for Elekta's success.
Products with High Maintenance Costs
Dogs in Elekta's portfolio are products with high maintenance costs and low returns. High equipment costs, need for skilled staff, and regulatory hurdles hinder profitability. Innovation should target cost reduction, user-friendliness, and integration. In 2024, Elekta's R&D spending was 12% of revenue, focusing on these areas.
- High Maintenance Costs: Products with significant upkeep expenses.
- Low Returns: Generating minimal profit or revenue.
- Impact of Costs: Equipment, personnel, regulatory factors.
- Innovation Focus: Reduce costs, improve ease of use.
Elekta's Brachytherapy: Low Returns & High Costs
Elekta's "dogs" struggle in low-growth markets with low market share. Older brachytherapy products face competition, potentially falling into this category. These products suffer from high maintenance and low returns, impacted by equipment costs and regulatory hurdles. In fiscal year 2023/2024, order intake decreased by 1% at constant exchange rates, reflecting these challenges.
| Feature | Impact | Data |
|---|---|---|
| Market Share | Low | Affected by competitors like Varian and Siemens. |
| Financials | Low Returns | Order intake decreased by 1% in fiscal year 2023/2024. |
| Maintenance | High Costs | Equipment, personnel, and regulatory expenses. |
Question Marks
Proton Therapy Solutions
Proton therapy is a burgeoning field within radiation therapy, offering highly targeted cancer treatment. Elekta's expansion in proton therapy solutions could tap into this growth; the global proton therapy market was valued at $728 million in 2024. This technology, like proton beam therapy, presents significant, yet still largely untapped, potential for Elekta. Consider that the market is projected to reach $1.4 billion by 2030.
AI-Driven Adaptive Therapy
AI-driven adaptive therapy instantly refines plans for enhanced precision and workflow efficiency. Elekta's investment in AI, like Elekta Evo, offers online and offline adaptive radiotherapy. In 2024, the global radiotherapy market was valued at $6.8 billion. Further development and marketing could elevate these AI solutions to "star" status.
Veterinary Radiation Therapy
Veterinary radiation therapy presents a niche market with growth possibilities, particularly for companies like Elekta. Elekta could diversify its revenue streams by expanding its offerings in this specialized area. While Elekta already has products in veterinary radiation therapy, further investment could increase market share. The global veterinary oncology market was valued at $305.2 million in 2024, projected to reach $475.1 million by 2030.
Expansion in Emerging Markets
Elekta's expansion in emerging markets is a key element of its growth strategy. These markets have a lower patient population per installed base compared to developed regions, presenting a significant opportunity. Elekta's ACCESS 2025 strategy directly targets low- and middle-income geographies, aiming to capitalize on this. Strategic focus on underpenetrated markets could transform them into "stars" within the BCG Matrix.
- ACCESS 2025 strategy targets low- and middle-income countries.
- Emerging markets offer significant growth potential.
- Focus on underpenetrated markets.
- Patient population per installed base is lower.
Integration with Theranostics
Elekta could benefit from integrating theranostics, a precision medicine approach using diagnostic biomarkers with targeted therapeutics. Collaborating with theranostics specialists could enhance Elekta's personalized cancer care solutions. GE HealthCare's partnership with Mayo Clinic highlights the potential of this area. This could lead to more effective and tailored cancer treatments.
- Theranostics combines diagnostics and therapy for personalized cancer treatment.
- Partnerships with theranostics companies could boost Elekta's offerings.
- GE HealthCare's ventures signal the growing importance of theranostics.
- This integration could improve treatment outcomes for patients.
Unlocking Growth: From Question Marks to Stars
Elekta's "Question Marks" are areas with high potential but uncertain returns in the BCG Matrix.
These include proton therapy, AI-driven solutions, veterinary radiation therapy, expansion into emerging markets, and theranostics integration.
Success depends on strategic investment and market execution to transform these into "Stars."
| Product/Strategy | Market Status | Elekta's Focus |
|---|---|---|
| Proton Therapy | Burgeoning; $728M (2024) | Expansion in proton therapy solutions. |
| AI-Driven Solutions | Growing; $6.8B (2024) radiotherapy market | Investment in AI, adaptive therapy. |
| Veterinary RT | Niche; $305.2M (2024) | Expanding offerings in veterinary oncology. |
BCG Matrix Data Sources
This Elekta BCG Matrix is built using public financial reports, market analysis data, and competitive intelligence for actionable insights.
